Life Sciences

PTC Therapeutics Acquiring Agilis and Gene Therapy Portfolio for $200 Million

PTC Therapeutics Acquiring Agilis and Gene Therapy Portfolio for $200 Million

Equities Research | |

Deal includes $745 million in potential additional milestone payments based on success of Agilis' central nervous system therapies.

Morphosys and Galapagos Sign License Deal with Novartis in Inflammatory Disease

Equities Research | |

Initial target is atopic dermatitis. Deal potentially worth $1.1 billion.

Geron's Imetelstat Reaffirmed as a Priority for Johnson & Johnson

Equities Research | |

JNJ CEO Alex Gorsky cites hematology-related oncology among "key catalysts for growth."

SIGA Technologies Gets FDA Approval for First Smallpox Therapeutic

Equities Research | |

Advances health security against a longstanding concern of smallpox as a potential bioterror threat. SIGA also gets priority review voucher for its next drug.

Crinetics Pharmaceuticals IPO Expected This Week For Rare Endocrine Disorders

Equities Research | |

Initial targets include acromegaly, hyperinsulinemia and neuroendocrine tumors.

Allakos IPO Expected Next Week for Antibody Immunotherapy Programs

Equities Research | |

Targeting receptors on eosinophils and mast cells to inhibit disease.

Zogenix Shows Positive Top-Line Results from 2nd Phase 3 Trial for Dravet Syndrome

Equities Research | |

Confirmatory data shows significant reduction in convulsive seizures in patients with this severe form of epilepsy.

Otsuka Pharmaceuticals to Acquire Visterra for $430 Million

Equities Research | |

Adding targeted antibody therapy platform and multiple kidney and infectious disease programs.

Constellation Pharmaceuticals Raising $80 Million in IPO to Advance Cancer Epigenetics

Equities Research | |

Lead programs in prostate cancer, solid tumors and myelofibrosis.

Rubius Therapeutics IPO Expected Next Week to Advance Cellular Therapy Platform

Equities Research | |

Initial focus on rare diseases, cancer and autoimmune diseases.

Emerging Growth

The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd through its subsidiary operates as a cannabinoid-based research and development company in Canada.


The MoneyShow San Francisco

Why should you join thousands of America's savviest investors and traders who make The MoneyShow San Francisco their can't-miss conference each summer? Because you will meet face-to-face and hear from…

Learn more